Health Condition 1: I700- Atherosclerosis of aorta
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Dr Reddys Laboratories Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Patients with documented history of atherosclerotic cardiovascular disease using dual antiplatelet drugs along with PPIs
Exclusion criteria
Exclusion criteria: Patients with a history of peptic ulcer or gastric or duodenal surgery Patients with erosive esophagitis and gastric-outlet obstruction Patients treated with multiple anti-ulcer medications Patients with severe pulmonary, hepatic, or renal disease Patients with incomplete records Patients on anticoagulants other than aspirin plus clopidogrel and on PPIs other than rabeprazole, pantoprazole and esomeprazole.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The outcome of co administration of various currently used PPIs with dual antiplatelet therapy in patients of atherosclerotic cardiovascular disease will be analyzed in terms of percentage of Myocardial infarction Stroke Unstable angina Heart failure Rehospitalization for cardiovascular related illness Repeat percutaneous coronary intervention or coronary artery bypass grafting Death Bleeding events Stent thrombosisTimepoint: Baseline to end of 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| The outcome of co administration of rabeprazole vs other PPIs (pantoprazole, esomeprazole) with dual antiplatelet therapy in patients of atherosclerotic cardiovascular disease will be analyzed in terms of percentage of Myocardial infarction Stroke Unstable angina Heart failure Rehospitalization for cardiovascular related illness Repeat percutaneous coronary intervention or coronary artery bypass grafting Death Bleeding events Stent thrombosisTimepoint: Baseline to end of 12 months | — |
Countries
India
Contacts
Public ContactDr Rahul Rathod
Dr Reddys Laboratories Limited
Outcome results
None listed